Gilead Sciences (GILD) Set to Announce Earnings on Thursday

Gilead Sciences (NASDAQ:GILD) is scheduled to be announcing its earnings results after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of $1.56 per share for the quarter. Gilead Sciences has set its FY24 guidance at $6.85-7.25 EPS and its FY 2024 guidance at 6.850-7.250 EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The business had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.67 EPS. On average, analysts expect Gilead Sciences to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $66.95 on Tuesday. Gilead Sciences has a 12-month low of $65.90 and a 12-month high of $87.86. The firm has a market capitalization of $83.36 billion, a price-to-earnings ratio of 14.88, a P/E/G ratio of 0.92 and a beta of 0.19. The stock’s 50 day moving average price is $71.81 and its two-hundred day moving average price is $76.51. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.60%. Gilead Sciences’s payout ratio is presently 68.44%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Mizuho decreased their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Royal Bank of Canada reduced their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a report on Wednesday, February 14th. UBS Group decreased their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Finally, Oppenheimer restated an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a research note on Friday. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $84.71.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.